导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -4.50% | 3365/4773 |
| 近一周 | -1.53% | 2278/5465 |
| 近一月 | -3.27% | 2327/5421 |
| 近一季 | -7.03% | 2630/5231 |
| 近半年 | -2.11% | 2014/4920 |
| 近一年 | -2.67% | 3066/4394 |
| 近两年 | 31.51% | 2222/2954 |
| 近三年 | 18.77% | 1538/2253 |
| 成立以来 | 10.77% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.62% 3657/4961 |
7.73% 2674/5312 |
- - |
- - |
| 2025 | 14.68% 2593/4813 |
-1.13% 2588/3635 |
2.49% 1537/4076 |
11.74% 3133/4524 |
1.27% 1446/4813 |
| 2024 | 19.39% 527/3463 |
5.01% 407/2808 |
0.12% 649/3014 |
17.39% 1197/3129 |
-3.27% 2313/3463 |
| 2023 | -10.50% 1310/2656 |
1.69% 1531/2280 |
-4.13% 1066/2385 |
0.04% 395/2515 |
-8.22% 2267/2655 |
| 2022 | -12.83% 302/2207 |
-11.53% 524/1919 |
10.24% 266/2016 |
-11.99% 621/2113 |
1.54% 1230/2208 |
| 2021 | -0.04% 735/1822 |
0.48% 291/1255 |
3.81% 953/1330 |
-6.80% 992/1466 |
2.81% 512/1822 |
| 2020 | - - |
- - |
- - |
- - |
- - |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华润元大富时中国A50指数C VS. 长安沪深300非周期A(740101) |